A breakthrough treatment for more patients1

Triple combination therapy for patients with CF aged 12 years and older, with at least one F508del mutation2

TRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one F508del mutation.


Get to Know Vertex GPS™: Guidance & Patient Support

Vertex GPS™ offers ongoing one-on-one support, right from the start of treatment. Patient Support Specialists can help you navigate questions about insurance, reimbursement, and co-pay assistance. You can even get tips for your Vertex treatment and resources that may help you stay on track. No matter where you’re headed, Vertex GPS™ is with you along the way.

Visit Vertex GPS™: Guidance & Patient Support


If you’ve already signed up:Login
CFTR, cystic fibrosis transmembrane conductance regulator.